Transmissibility of murine stem cell virus-based retroviral vectors carrying both interleukin-12 cDNAs and a third gene: Implications for immune gene therapy

Cancer Gene Therapy

Volumn 4, Issue 3, 1997, Pages 167-175

  Lieu, Francis H L ^a   Hawley, Teresa S ^a   Fong, Andrew Z C ^a   Hawley, Robert G ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cancer gene therapy; IL 12; MSCV; Multigenic retroviral vectors

Indexed keywords

ACYLTRANSFERASE; INTERLEUKIN 12; INTERLEUKIN 9; PUROMYCIN N ACETYLTRANSFERASE; PUROMYCIN N-ACETYLTRANSFERASE;

ANIMAL; ARTICLE; B CELL LYMPHOMA; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CULTURE; DBA MOUSE; EVALUATION; GENE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; MOUSE; RETROVIRUS; T CELL LYMPHOMA;

ACETYLTRANSFERASES; ANIMALS; EVALUATION STUDIES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; INTERLEUKIN-12; INTERLEUKIN-9; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0031133177     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. d'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med. 1992;176: 1387-1398.
2. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827-845.
3. Stern AS, Podlaski FJ, Hulmes JD, et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 1990;87:6808-6812.
4. Gately MK, Wilson DE, Wong HL. Synergy between recombinant interleukin-2 (rIL-2) and IL-2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro. J Immunol. 1986;136:1274-1282.
5. Mehrotra PT, Wu D, Crim JA, et al. Effects of IL-12 on the generation of cytolytic activity in human CDS+ T lymphocytes. J Immunol. 1993;151:2444-2452.
6. Bloom ET, Horvath JA. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. J Immunol. 1994;152:4242-4254.
7. McKnight AJ, Zimmer GJ, Fogelman L, et al. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol. 1994;152:2172-2179.
8. Kennedy MK, Picha KS, Shanebeck KD, et al. Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol. 1994;24:2271-2278.
9. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 1995;13:251-276.
10. Biron CA, Gazinelli RT. Effects of IL-12 on immune responses to microbial infections. Curr Opin Immunol. 1995;7:485-496.
11. Brunda M, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med. 1993;178:1223-1230.
12. Nastala CL, Edington HD, McKinney TG, et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 1994; 153:1697-1706.
13. Noguchi Y, Richards EC, Chen Y-T, et al. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA. 1995;92: 2219-2223.
14. Coughlin CM, Wysocka M, Kurzawa HL, et al. B7-1 and interleukin-12 synergistically induce effective antitumor immunity. Cancer Res. 1995;55:4980-4987.
15. Vagliani M, Rodolfo M, Cavallo F, et al. Interleukin-12 potentiates the curative effect of a vaccine based on interleukin-2-transduced tumor cells. Cancer Res. 1996;56: 467-470.
16. Rao JB, Chamberlain RS, Bronte V, et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J Immunol. 1996;156:3357-3365.
17. Brunda MJ, Luistro L, Hendrzak JA, et al. Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12. J Immunother. 1995;17:71-77.
18. Voest EE, Kenyon BM, O'Reilly MS, et al. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-596.
19. Kerbel RS, Hawley RG. Interleukin 12: newest member of the antiangiogenesis club. J Natl Cancer Inst. 1995;87:557-559.
20. Tahara H, Zeh HJ III, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994;54:182-189.
21. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol. 1995;155:1393-1403.
22. Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol. 1995;154:6466-6474.
23. Martinotti A, Stoppacciaro A, Vagliani M, et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol. 1995;25:137-146.
24. Colombo MP, Vagliani M, Spreafico F, et al. Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res. 1996;56:2531-2534.
25. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555-562.
26. Jiang Y-Z, Kanfer EJ, Macdonald D, et al. Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells. Bone Marrow Transplant. 1991;8:253-258.
27. Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood. 1993;8:2273-2277.
28. Hawley RG, Lieu FHL, Fong AZC, et al. Retroviral vectors for production of interleukin-12 in the bone marrow to induce a graft-versus-leukemia effect. Ann NY Acad Sci. 1996;795:341-345.
29. Hawley RG, Fong AZC, Burns BF, et al. Transplantable myeloproliferative disease induced in mice by an interleukin-6 retrovirus. J Exp Med. 1992;176:1149-1163.
30. Hawley RG, Fong AZC, Ngan B-Y, et al. Progenitor cell hyperplasia with rare development of myeloid leukemia in interleukin 11 bone marrow chimeras. J Exp Med. 1993; 178:1175-1188.
31. Hawley RG. Hematopathology of interleukin 6-type cytokines. Stem Cells. 1994;12(suppl 1):155-171.
32. Hawley RG, Fong AZC, Lu M, et al. The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene. 1994;9:1-12.
33. Hawley RG, Fong AZC, Ngan B-Y, et al. Hematopoietic transforming potential of activated ras in chimeric mice. Oncogene. 1995;11:1113-1123.
34. Ally BA, Hawley TS, McKall-Faienza KJ, et al. Prevention of autoimmune disease by retroviral-mediated gene therapy. J Immunol. 1995;155:5404-5408.
35. Yan Y-Q, Lacey D, Fletcher F, et al. Chronic exposure to retroviral vector encoded MGDF (mpl-ligand) induces lineage-specific growth and differentiation of megakaryocytes in mice. Blood. 1995;86:4025-4033.
36. Hawley RG, Hawley TS, Fong AZC, et al. Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11. Proc Natl Acad Sci USA. 1996;93:10297-10302.
37. phox. Blood. 1996;88:1834-1840.
38. Conneally E, Bardy P, Eaves CJ, et al. Rapid and efficient selection of human hematopoietic cells expressing murine heat-stable antigen as an indicator of retroviral-mediated gene transfer. Blood. 1996;87:456-464.
39. Hawley RG, Lieu FHL, Fong AZC, et al. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138.
40. Hawley RG. Therapeutic potential of retroviral vectors. Transfus Sci. 1996;17:7-14.
41. Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA. 1991;88:4143-4147.
42. Guattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol. 1991;11:5848-5859.
43. Hantzopoulous PA, Sullenger BA, Ungers G, et al. Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc Natl Acad Sci USA. 1989;86:3519-3523.
44. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol. 1992;148: 3433-3440.
45. Thomas KR, Capecchi MR. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 1987;51:503-512.
46. Markowitz D, Goff S, Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 1988;62:1120-1124.
47. Hawley TS, Sabourin LA, Hawley RG. Comparative analysis of retroviral vector expression in mouse embryonal carcinoma cells. Plasmid. 1989;22:120-131.
48. Hawley TS, Lach B, Burns BF, et al. Expression of retrovirally transduced IL-1α in IL-6-dependent B cells: a murine model of aggressive multiple myeloma. Growth Factors. 1991;5:327-338.
49. Hyman R, Ralph P, Sarkar S. Cell-specific antigens and immunoglobulin synthesis of murine myeloma cells and their variants. J Natl Cancer Inst. 1972;48:173-184.
50. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, et al. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol. 1979;122:549-554.
51. Law LW, Dunn TB, Boyle PJ, et al. Observations on the effect of a folic-acid antagonist on transplantable lymphoid leukemias in mice. J Natl Cancer Inst. 1949;10:179-191.
52. Warner NL, Moore MAS, Metcalf D. A transplantable myelomonocytic leukemia in BALB/c mice: cytology, karyotype, and muraminidase content. J Natl Cancer Inst. 1969;43:963-982.
53. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol. 1973;242:148-149.
54. Bell C, Frost P, Kerbel RS. Cytogenetic heterogeneity of genetically marked and metastatically competent "dominant" tumor cell clones. Cancer Genet Cytogenet. 1991;54: 153-161.
55. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory; 1989.
56. Piechaczyk M, Blanchard JM, Marty L, et al. Post-transcriptional regulation of glyceraldehyde-3-phosphate-de-hydrogenase gene expression in rat tissues. Nucleic Acids Res. 1984;12:6951-6963.
57. Xu H, Rizzo LV, Caspi RR. IL-12 induces growth of the IL-4-dependent CT4S line and has a synergistic effect on IL-4-induced CT4S proliferation. J Immunol Meth. 1995; 181:245-251.
58. Jang SK, Kräusslich H-G, Nicklin MJH, et al. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J Virol. 1988;62:2636-2643.
59. Jang SK, Wimmer E. Cap-independent translation of encephalomyocarditis virus RNA: structural elements of the internal ribosomal entry site and involvement of a cellular 57-kD RNA-binding protein. Genes Dev. 1990;4: 1560-1572.
60. Mattner F, Fisher S, Guckes S, et al. The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol. 1993;23:2202-2208.
61. Gillessen S, Carvajal D, Ling P, et al. Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist. Eur J Immunol. 1995;25:200-206.
62. Zitvogel L, Tahara H, Cai Q, et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Human Gene Ther. 1994;5:1493-1506.
63. Junker U, Böhnlein E, Veres G. Genetic instability of a MoMLV-based antisense double-copy retroviral vector designed for HIV-1 gene therapy. Gene Ther. 1995;2:639-646.
64. Emerman M, Temin HM. Comparison of promoter suppression in avian and murine retrovirus vector. Nucleic Acids Res. 1986;14:9381-9396.
65. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell. 1984;39:459-467.
66. Temin HM. Retrovirus vectors for gene transfer: efficient integration into and expression of exogenous DNA in vertebrate cell genomes. In: Kucherlapati R, ed. Gene Transfer. New York: Plenum Press; 1986:149-187.